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Helicobacter pylori infects 50% of mankind. The vast majority ofH. pylori infection occurs in the developing countries where up to 80% of the
middle-aged adults may be infected. Bacterial infection causes an inflammatory response that proceeds through a series of intermediated
stages of precancerous lesions (gastritis, atrophy, intestinal metaplasia, and dysplasia). Among infected individuals, approximately 10%
develops severe gastric lesions such as peptic ulcer disease, 1–3% progresses to gastric cancer (GC) with a low 5-year survival rate,
and 0.1% develops mucosa-associated lymphoid tissue (MALT). GC is one of the most common cancer and the third leading cause of
cancer-related deaths worldwide. In this review, we have summarized the most recent papers about molecular mechanisms of H. pylori
pathogenesis. The main important steps of H. pylori infection such as adhesion, entry in epithelial gastric cells, activation of intracellular
pathways until epigenetic modifications have been described.
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Helicobacter pylori is considered the most common etiologic
agent worldwide in adults and children. It infects 50% of
mankind (Parreira et al., 2013) and represents the most
important risk factor for gastric malignancies (Wang et al.,
2014). For this reason, the International Agency for Research
on Cancer (IARC) has classified it as a class I carcinogen (IARC,
1994). The prevalence of H. pylori varies with the geographic
regions, age, socio-economic status, educational level, living
environment, and occupation (Wang et al., 2014). The vast
majority of H. pylori infection occurs in the developing
countries where up to 80% of the middle-aged adults may be
infected (Wang and Peura, 2011; Wang et al., 2014). Natural
acquisition of H. pylori infection occurs, for the most part, in
childhood via fecal–oral and oral–oral pathways (Alvarez et al.,
2013a; Sampieri, 2013). Infection induces an inflammatory
response that does not eradicate the bacterial colonization, but
which persists for the lifetime of the individual (Logan and
Walker, 2001; Parreira et al., 2013). The slow sequence, known
as Correa’s cascade (Correa, 1992) passes through a series of
intermediated stages of precancerous lesions in the following
order: gastritis, atrophy, intestinal metaplasia, and eventually
dysplasia (Boreiri et al., 2013). Among infected individuals,
approximately 10% develops severe gastric lesions such as
peptic ulcer disease, 1–3% progresses to gastric cancer (GC)
with a low 5-year survival rate (Cirak et al., 2007), and 0.1%
develops mucosa-associated lymphoid tissue (MALT)
lymphoma (Noto and Peek, 2012; Parreira et al., 2013; Wang
et al., 2014) (Fig. 1). It is estimated that individuals infected with
H. pylori have more than twofold increased risk of developing
GC compared with non-infected ones (Queiroz et al., 2012;
Demirel et al., 2013). Although a dramatic decline in the
incidence and mortality has been observed in recent decades,
GC is one of the most common cancer and the third leading
cause of cancer-related deaths worldwide with more than
700,000 deaths annually (Melton et al., 2010; Boreiri et al.,
2013; Shiotani et al., 2013). GC is an insidious disease, often
manifesting its symptoms at an advanced stage when few
therapeutic options are available with even less efficiency
(Boreiri et al., 2013). GC arises from hyperproliferation of
the stomach epithelial cells and are accompanied by
hypochlorhydria (low-acid secretion), and atrophic gastritis
(Fox et al., 2006; Osman et al., 2013).
H. pylori gastritis is characterized by infiltration of the
gastric mucosa with both acute inflammatory cells
(polymorphonuclear leukocytes) and chronic inflammatory
cells (lymphocytes, plasma cells, and macrophages). H. pylori
initially are predominantly localized at the antrum, a site
where parietal (acid producing) cells are absent and thus acid
secretion is not directly affected (Shiotani et al., 2013). The
progression and severity of the gastritis pattern depend on an
interaction of multiple factors:
(1) H. pylori features including genomic plasticity, capacity for
adaptation to the individual host conditions, modulation of the
reaction to the host immune system response and presence
and production of various virulence factors;
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(2) host factors, for example, genetic background or physiological
and immunological state, especially those that enhance or
reduce the inflammatory response to the infection;
(3) the environmental factors such as smoking, diet, high salt, and
meat consumption (Hnatyszyn et al., 2013; Sampieri, 2013;
Shiotani et al., 2013).
Only a subset of infected individuals develops serious gastric
disease and the mechanism of H. pylori pathogenicity is not well
understood (Lillehoj et al., 2012; Chiariotti et al., 2013). The
mechanism by which H. pylori causes disease in humans can be
described as a multi-step process where the bacterium first has
to evade the bactericidal activity of the gastric acid barrier and
enter the mucous layer (colonization) and then it has to adapt
and multiply under the environmental conditions of the gastric
mucus (persistence) (De Luca et al., 2004; Manente et al., 2008).
Several bacterial virulence factors have been associatedwith the
development of gastric diseases. The first step, essential in
successful infection, is the adhesion of H. pylori to the host
gastric mucosa and bacterial motility. This event triggers the
expression of several bacterial genes, including some that
encode virulence factors, and protects the pathogen from
clearance mechanisms such as liquid flow, peristaltic move-
ments, or shedding of the mucous layer (Kim et al., 2004;
Parreira et al., 2013). Adhesion is mediated by H. pylori surface-
bound proteins, termed adhesins, that recognize glycan
structures (Gly-Rs) expressed on the surface of gastric
epithelial cells and are also present on themucus layer lining the
gastric mucosa (Ilver et al., 1998; Mahdavi et al., 2002;
Goncalves et al., 2013; Parreira et al., 2013). The blood group
antigen binding adhesin (BabA) recognizes fucosylated blood
group antigens, including the difucosylated Lewis antigens, such
as the Lewis b (Leb) antigen and H type 1 histo-blood group
carbohydrate structures expressed in the gastric epithelium and
mucus layer (Goncalves et al., 2013; Parreira et al., 2013).
Infection with H. pylori strains expressing functional BabA have
been correlated with an increased risk of gastric carcinoma
(Ilver et al., 1998; Gerhard et al., 1999; Yamaoka et al., 2002;
Parreira et al., 2013). The sialic acid-binding adhesin (SabA)
mediates bacterial adherence to gastric mucosa through the
bound with sialylated carbohydrate structures such as sialyl
Lewis x and sialyl Lewis a (Mahdavi et al., 2002; Aspholm et al.,
2006; Goncalves et al., 2013). Urease and flagellin have been
recognized as important factors for bacterial colonization of the
gastric mucosa (Dunn and Phadnis, 1998; O’Toole et al., 2000;
Perrais et al., 2014). Urease is able to convert urea into
ammonia and carbon dioxide in order to form an acid-
neutralizing cloud of ammonia, elevating the pH to neutral, and
protect the bacterium from gastric acidity (Celli et al., 2009;
Perrais et al., 2014). Urea hydrolysis is accomplished by uptake
of urea through a proton-gated channel that allows hydrolysis
inside the bacterium and creating a thin neutral layer around the
outer surface of the cell (Weeks et al., 2000; Celli et al., 2009).
Moreover, it has been shown that urease can exist also on the
cell surface (Phadnis et al., 1996; Dunn and Phadnis, 1998; Baik
et al., 2004; Celli et al., 2009), or in the stomach environment
(Vanet and Labigne, 1998; Gobert et al., 2002; Celli et al., 2009).
Once the bacterium has created a favorable environment in
term of pH, the next step is the ability to swim through the
protective layer of the gastric mucus in the host stomach (Celli
et al., 2009). It has been demonstrated that urease induced pH
elevation of H. pylori reduces viscoelasticity in the mucin gel,
triggering the transition from gel to sol of gastric mucin and
enables the bacteria to move freely through the mucus (Celli
et al., 2009). Flagella (5–7 per cell) confer motility to the cells;
they are made of polymers of two subunits, the major flagellin
FlaA and the minor flagellin FlaB (Perrais et al., 2014). Other
than these factors cited above, an other important protein, the
HelicobacterD,D-peptidase A (HdpA) has been identified for its
involvement in determiningH. pylori shape (Bonis et al., 2010). It
has been demonstrated that mutation of HdpA induces
abnormal shape and reduces the ability of H. pylori to colonize
the gastric mucosa (Bonis et al., 2010). Moreover, H. pylori
produces a variety of virulence factors able to deregulate host
intracellular signaling pathways. Among all the virulence factors,
Cag A (cytotoxin-associated geneA) and its pathogenicity island
(Cag PAI), VacA (vacuolating cytotoxin A), heat shock protein B
(HspB) (Iaquinto et al., 2000; De Luca et al., 2008), and the
duodenal ulcer promoting gene A (DupA) are considered the
major pathogenic factors (Lee and Derakhsham, 2013; Wang
et al., 2014) (Fig. 2).
Molecular Mechanism of H. pylori Pathogenesis
The H. pylori genome consists of 1.65 million bp and codes for
about 1,500 proteins (Tomb et al., 1997; Alm and Trust, 1999;
Fig. 1. Sequence of subsequent events from bacterial transmission to the host until precancerous and gastric lesions induced by H. pylori.
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De Luca et al., 2004). However, H. pylori populations are
extremely different, as a result of point mutations,
substitutions, insertions, and/or deletions in their genome
(Blaser and Berg, 2001; Buommino et al., 2012).
Adhesion to gastric epithelium
The stomach is protected from its own gastric juice by a thick
layer of mucus that covers the stomach lining (Penta et al.,
2005). The mucus layer is formed by high molecular weight and
heavily glycosylated glycoproteins known as mucins, whose
function is to protect gastric epithelial cells against chemical,
enzymatic, microbial, and mechanical damage. Mucins act as
diffusion barrier to acidic HCl instilled into the lumen of the
stomach and alkaline bicarbonate ions secreted by the gastric
epithelium, maintaining a gradient from around pH 1.2–2.5 in
the gastric lumen to pH 7.4 near the epithelial surface
(Bhaskar et al., 1992; Goncalves et al., 2013). H. pylori resides
within the mucus of the stomach and duodenum and about 1%
of the colonizing bacteria adheres to the apical surface of
epithelial cells where they attach firmly via adhesin molecules
and via modifications of cell membrane proteins and of
cytoskeletal proteins (De Luca et al., 2004). This ecological
niche requires special features to survive, but offers the
advantage of little competition from other bacterial species
(Montecucco et al., 1999; De Luca et al., 2004). MUC5AC
mucin, the major component of the mucosal layer, is closely
related to H. pylori and plays a role in the adhesion of this
bacterium to the gastric mucosa (Van den Brink et al., 2000;
Van de Bovenkamp et al., 2003; Shi et al., 2014). The expression
level of MUC5AC is gradually decreased during the
progression of types I, II, and III intestinal metaplasia and in the
progression of H. pylori positive pre-neoplastic lesions to
gastric adenocarcinoma (Machado et al., 2000; Shi et al., 2014).
Particularly, the MUC5AC is lower in cancer tissues with more
than five metastatic lymph nodes and positive to H. pylori as
compared with that of the cancer tissues with five or less
metastatic lymph nodes, which demonstrates that cancer
progression might be related with the MUC5AC expression
level (Shi et al., 2014). Recently, it has been reported that
urease mediates downregulation of MUC5AC transcription in
gastric cancer cells, since MUC5AC promoter contains UreB-
responsive elements (Perrais et al., 2014). Moreover, UreB-
and FlaA-responsive elements in the promoters of MUC2,
MUC5AC, and MUC5B and CagA-responsive elements in the
promoters of MUC2 and MUC5B have been identified (Perrais
et al., 2014). These results suggest that different bacterium
virulence factors act during infection and development of
gastric malignancies (Perrais et al., 2014).H. pylori is also able to
inhibit the total mucin synthesis and causes significant
alterations of the structure and function of gastric mucins
(Fichman and Niv, 2004; Kocer et al., 2004; Marques et al.,
2005; Kang et al., 2008; Lillehoj et al., 2012; Shi et al., 2014),
which may be the key events in the progression to gastric
cancer or malignant transformation (Nomura et al., 2004; Sun
et al., 2005; Shi et al., 2014).
Activation of intracellular pathways of gastric
epithelial cells
H. pylori strains can be divided into two broad families, type I
and type II, based on the presence of the cag pathogenicity
island (PAI), an approximately 40 kb locus composed of 31
genes (Censini et al., 1996; Tomb et al., 1997; De Luca et al.,
2004) including the CagA protein and the Cag type IV secretion
system (T4SS). The T4SS forms a needle-like structure
protruding from the bacterial surface by which CagA can be
inserted into the target host cells (Tegtmeyer et al., 2011; Ling
et al., 2013; Wang et al., 2014). A member of T4SS is CagL that
is able to target the T4SS to host a5b1 integrin receptor on the
epithelial cell membrane (Delahay and Rugge, 2012).
It has also been demonstrated that CagL interacts with avb3
and avb5 receptors responsible of the activation of the gastrin
promoter (Wiedemann et al., 2012). CagL interacts with CagI
(Shaffer et al., 2011; Pham et al., 2012) and CagH (Shaffer et al.,
2011) forming a surface exposed T4SS subassembly required
for pilus biogenesis (Delahay and Rugge, 2012). CagM is
localized mainly in the bacterial membrane, partially in the
periplasm. It is essential for CagA translocation and probably is
one of the members of the transmembrane channel of T4SS
(Ling et al., 2013). Once translocated in the host cytoplasm,
CagA may bind to the inner surface of the cell membrane and
undergoes tyrosine phosphorylation of its C-terminal A–B–C
or D type glutamate–proline–isoleucine–tyrosine–alanine
(EPIYA) motif by Src family kinases and c-Abl (Delahay and
Rugge, 2012; Wang et al., 2014). The entry of CagA into the
Fig. 2. Schematic representation of some bacterial factors involved in different stages of H. pylori pathogenicity.
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cytoplasm through the ectodomain of a5b1 integrin, induces
its interaction with a number of host proteins in order to
activate downstream signal pathways, such as Ras/mitogen-
activated protein kinase (MEK)/extracellular signal-regulated
kinase (ERK) pathway (Mueller et al., 2012; Xu et al., 2012),
nuclear factor kB (NF-kB) pathway, and b-catenin pathway
(Wang et al., 2014). All these interactions between bacterial
and host proteins allow the deregulation of epithelial cell
polarity (cell elongation and scattering) and the acquisition of
the so called “humming bird” phenotype (mediated by
interaction with Src-homology protein tyrosine phosphatase
(SHP) 2), disruption of tight junctions (impairing E-cadherin/b-
catenin complex; inhibition of the kinase partitioning-defective
1b/microtubule affinity-regulating kinase 2-PAR1b/MARK2)
and cell apical junction complex (interacting with several
junction proteins such as zonulaoccludens 1, junctional adhesion
molecule A). All these processes are able to facilitate the
malignant transformation and development of intestinal
metaplasia (Kaplan-Turkoz et al., 2012; Wang et al., 2014).
CagA is also able to interact with the apoptosis-stimulating
protein of p53 (ASPP2) that normally induces apoptosis
following DNA damage by activating the tumor suppressor p53
(Delahay and Rugge, 2012). CagA misregulates ASSP2 leading
to proteosomal degradation of p53 and consequently evokes
an antiapoptotic response (Buti et al., 2011; Delahay and Rugge,
2012). In this view, it has been demonstrated that H. pylori
CagAþ strains significantly increase the risk of developing
severe gastritis, atrophic gastritis, peptic ulcer, and distal
gastric cancer (De Luca et al., 2004). Moreover, CagM and
CagL components of T4SS mechanistically involve in NF-kB
activation (Smolka and Backert, 2012) and in the repression of
HKa transcription, which causes the downregulation of human
gastric H/K-ATPase expression, significantly inhibiting acid
secretion by gastric cells (Saha et al., 2010; Ling et al., 2013). On
the other hand, VacA product might contribute to the
pathogenicity of H. pylori inducing vacuolation of gastric cells,
apoptotic events, and alteration in cell cycle (De Luca et al.,
2004; Manente et al., 2008; Buommino et al., 2012). This
protein inserts itself into the epithelial cell membrane and
facilitates the formation of transmembrane pores which
permeabilize the gastric epithelium to urea (Szabo et al., 1999;
Tombola et al., 1999; Jungblut et al., 2000), probably also
providing the bacterium with nutrients (De Luca et al., 2004;
Manente et al., 2008). It has been demonstrated that VacA
overexpression in AGS cells induces a stop of G1 phase of the
cell cycle and an increase in the percentage of apoptotic cells by
activation of mitochondrial pathway (Manente et al., 2008). It
has been shown that H. pylori VacA-secreting strains are more
common among patients with distal gastric cancer than among
patients with gastritis alone (Miehlke et al., 2000; De Luca et al.,
2004). It is well known that H. pylori infection causes chronic
oxidative stress on gastric mucosa, thereby causing mucosal
damage and retarding mucosal repair (Hahm et al., 1998; De
Luca and Iaquinto, 2004). Although host cells act to protect
themselves against chronic oxidative stress by enhancing
activities of antioxidant enzymes (Buommino et al., 2012), it has
been demonstrated that HspB interferes with nuclear factor
erythroid-2-related factor 2 (Nrf2) pathway that coordinates
induction of genes encoding numerous antioxidant and phase II
detoxifying enzymes and related proteins (Buommino et al.,
2012). Particularly, HspB stabilizes the complex among Nrf2
and its repressor molecule Keap 1 (Kelch-like ECH-associated
protein 1), so impeding the translocation of Nrf2 into the
nucleus and the consequent activation of ARE gene
transcription. Consequently, H. pylori-infected cells are
impeded to activate the antioxidant response (Buommino
et al., 2012). Moreover, co-expression of CagA and HspB in
AGS cells is able to induce cell cycle proliferation through an
increase of rate of transit between the S/G2-M phase of the cell
cycle associated with a specific increase in cyclin D3 and
Retinoblastoma gene product, Rb, in its phosphorylated form
(De Luca et al., 2003, 2008). Hence, HspB deserves great
attention since it has been demonstrated that its activity
increases the risk of gastric carcinoma (Iaquinto et al., 2000).
The H. pylori-infected stomach displays dramatic
morphological changes in the cytoskeleton (Osman et al., 2013).
Several studies point their attention on the preventing of cell
migration by H. pylori by subverting the dynamics of focal
adhesions (FAs) (Tsutsumi et al., 2006; Schneider et al., 2008) in
order to maintain non-polarized, but immotile, phenotype with
reduced acid secretion, as a refuge (Osman et al., 2013). It has
been demonstrated that bacterial infection increases IQGAP1
transcript level involved in cell polarity, growth, and
proliferation (Conlin et al., 2004; Osman et al., 2013). The
increase of IQGAP1 expression level enhances IQGAP1’s
serine phosphorylation and binding to activated Cdc42-GTP
(Rittmeyer et al., 2008) and promotes cell migration and
invasion (Wang et al., 2009). Once activated, IQGAP1-Cdc42
complex dissociates adherent junctions (AJs) by delocalizing a-
catenin from E-cadherin–a-catenin–b-catenin complex, leading
to translocation of b-catenin to the nucleus and onset of
oncogenic transcriptional events responsible of cell scattering,
increasingmigration, and invasion (Noritake et al., 2005; Osman
et al., 2013). In addition, H. pylori infection promotes gastric
epithelial cells invasion by activating metalloproteinases (MMP),
important in tissue destruction and remodeling (Wu et al.,
2005). Particularly, HspB induces a strong increase inMMP3 and
MMP7 (Buommino et al., 2012). MMP7 influences cellular
proliferation and apoptosis and is overexpressed in gastric
malignancies (Honda et al., 1996). Increased MMP7 secretion
has been reported in the gastric epithelial cells of patients
infected withH. pylori, relative to subjects withH. pylori negative
dyspepsia (Wroblewski et al., 2003; Sampieri, 2013). Moreover,
it has been observed that migration is greater in cells belonging
to H. pylori positive subjects, compared with H. pylori negative
subjects (Wroblewski et al., 2003; Sampieri, 2013). It has been
suggested that overexpression of MMP1 (Wu et al., 2006) and
MMP7 (Crawford et al., 2003; Ogden et al., 2008) is dependent
upon the pathogenicity island of H. pylori (Sampieri, 2013).
Moreover, H. pylori strongly increases enzymatic activity of
MM9 and induces its secretion via NF-kB (Wu et al., 2005; Nam
et al., 2011), COX-2 (Wu et al., 2005), and ERK (Nam et al.,
2011).
Epigenetic modifications of gastric epithelial cells
induced by H. pylori
H. pylori-induced GC is an example of inflammation-associated
malignancy. This condition is associated with DNAmethylation
(Alvarez et al., 2013a). Several studies have demonstrated a
close association between H. pylori infection and aberrant CpG
island methylation (Chan et al., 2003; Maekita et al., 2006;
Nakajima et al., 2009). During the Correa’s cascade, promoter
hypermethylation is a commonly observed epigenetic change in
major tumor suppressor genes (Wang et al., 2014). Epigenetic
mechanisms may operate at gene-specific level in order to
regulate gene expression, the maintenance of DNA integrity
and stability (Alvarez et al., 2013b). These processes include
both chromatin modifications, orchestrated by chromatin-
remodeling complexes and histone-modifying enzymes, and
DNA methylation, directed by DNA methyltransferase (for
review see Chiariotti et al., 2013). Although the mechanism of
induction of DNA methylation by H. pylori is unknown, it is
believed thatH. pylori possess multiple DNAmethyltransferase
in T4SS that can directly induce gene methylation in epithelial
cells (Wang et al., 2014). Aberrant methylation-induced
silencing also occurs in several tumor suppressor genes such as
those involved in cell adhesion (E-cadherin) (Grady et al., 2000;
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Tamura et al., 2000; Chiariotti et al., 2013), and several other
genes, including those related to cell growth control (p16, p14,
and APC), DNA repair (mismatch repair gene – hMLH1;
BRCA1, MGMT) (Liu et al., 2012; Loh et al., 2012; Cheng et al.,
2013; Chiariotti et al., 2013; Wang et al., 2014). These changes
are strongly correlated with increased risk for GC (Wang et al.,
2014) since DNA methylation is a potent mechanism for
silencing gene expression and maintaining genome stability
(Chiariotti et al., 2013). It has been shown that 26 genes were
hypermethylated in individuals with current or past H. pylori
infection (Nakajima et al., 2009; Chiariotti et al., 2013).
Recently, it has been demonstrated that prolonged bacterial
infections lead to saturation of the repair capabilities of the
host cells and thus to an ineffective and mutagenic DNA repair
system (Toller et al., 2011; Alvarez et al., 2013b). So, H. pylori
infection-mediated DNAmethylation in adults may depend not
only on the level of the inflammatory response but also on the
persistence and duration of the infection (Alvarez et al., 2013b).
Until now about 20microRNAs (miRNAs) have been shown
to change in response to H. pylori infection (for review see
Nishizawa and Suzuki, 2013). Particularly, the miRNAs changed
in response to H. pylori are involved in different biological
processes such as cell cycle progression, apoptosis,
proliferation, invasion, metastasis, and immune response
(Nishizawa and Suzuki, 2013). Some miRNas such as miR-584
and miR-1290 are upregulated in CagA-transformed cells while
others such as let-7, miR6a, andmiR-101 are downregulated by
CagA (Nishizawa and Suzuki, 2013). This process suggests a
new pathogenic mechanism for CagA.
Conclusions
Several studies have been published in the last years about
mechanisms ofH. pylori infection. They point their attention on
the particular bacterial strategy that aims to avoid and/or
combat a negative response by host-infected cells. H. pylori is
able to integrate inside epithelial gastric cells in order to induce
the most favorable conditions for its colonization and growth.
The knowledge of molecular mechanisms of bacterial
infections may help to realize an early eradication and therapy.
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